Article

Contralateral Breast Cancer in BRCA1/BRCA2 Mutation Carriers: The Story of the Other Side

Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Journal of Clinical Oncology (Impact Factor: 18.43). 10/2009; 27(35):5862-4. DOI: 10.1200/JCO.2009.25.1652
Source: PubMed
0 Followers
 · 
86 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Le concept de médecine personnalisée s’est fortement développé dans la prise en charge des cancers du sein ces dernières années. Il repose sur des tests biologiques complexes, sur la tumeur évaluant le pronostic et la sensibilité de la maladie aux traitements potentiels. La génétique constitutionnelle est aujourd’hui capable d’apporter des informations essentielles et complémentaires aux données somatiques, en matière de pronostic local et général, mais surtout en termes de risque de nouveau cancer. Dans les années qui viennent, elle sera essentielle pour l’évaluation de la sensibilité potentielle spécifique aux thérapeutiques, en particulier avec l’arrivée de thérapeutiques ciblées spécialisées (les inhibiteurs de poly[ADP-ribose] polymérase [PARP] étant les chefs de file en cas d’anomalies constitutionnelles de réparation de l’ADN par exemple). Dans certains cas très rares, la sensibilité thérapeutique peut être excessive, comme en cas de présence d’une anomalie constitutionnelle de type p53 qui peut contre-indiquer les radiations ionisantes. Cette revue fait le bilan de nos connaissances en matière d’impact de la génétique constitutionnelle dans la prise en charge personnalisée des cancers du sein en 2010 et les modifications attendues dans les années à venir. The concept of personalized medicine has rapidly become a major part of breast cancer care. It relies on complex biological evaluations and predictions of both the prognostic and the specific treatment sensitivity of a single tumor and a single individual. Germline genetics can currently provide information that appears complementary to that provided by somatic analyses, regarding local and general prognosis of the current cancer and also subsequent cancer risk. In the next few years, germline genetic data should also have a major role to play in the evaluation of potential sensitivity to medical treatments (treatments targeting DNA repair such as the recently emerging PARP inhibitors), and therefore guide major treatment choices. This paper summarizes current existing data regarding the potential impact of germline genetics in the personalized care of breast cancer patients in 2010 and the evolutions expected in the coming years. Mots clésOncogénétique-BRCA1-BRCA2-Cancer du sein-Prise en charge-Mastectomie prophylactique-p53-Radiothérapie KeywordsBreast cancer care-Genetics-BRCA1-BRCA2-Prophylactic mastectomy-p53
    Oncologie 04/2010; 12(4):248-254. DOI:10.1007/s10269-010-1877-8 · 0.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The discovery of genes BRCA1 and BRCA2 has led to the introduction of genetic tests more complex every time for the evaluation ofthehereditarycancerrisk,amongothers.In the present paper we explore the criteria to decide when to run the testing for the genes, as well as the implications for the treatment of patients who are identified with them.
    Salud publica de Mexico 10/2011; 53(5):420-429. · 0.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Personalized medicine-the use of genomics and molecular diagnostics to direct care decisions-may improve outcomes by more accurately individualizing treatment to patients. Using qualitative research, we explored care delivery barriers to the use of personalized medicine for patients with breast cancer using examples of BRCA and gene expression profile testing. We conducted 51 interviews with multidisciplinary stakeholders in breast cancer care: clinicians (n = 25) from three academic and nine nonacademic organizations, executives (n = 20) from four major private insurers, and patient advocates (n = 6). Barriers were common to the BRCA and gene expression profile tests and were classified under two categories: poor coordination of tests relative to treatment decisions and reimbursement-related disincentives. Perception of specific barriers varied across groups. Difficulty coordinating diagnostics relative to decisions was the most frequent concern by clinicians (60%), but only 35% of payers and 17% of advocates noted this barrier. For 60% of payers, drug- and procedure-based reimbursement was a significant barrier, but only 40% of clinicians and none of the advocates expressed the same concern. The opinion that patient out-of-pocket expenses are a barrier varied significantly between advocates and clinicians (83% v 20%, P < .007), and advocates and payers (83% v 15%, P < .004). Barriers were reported to result in postponement or avoidance of tests, delayed treatment decisions, and proceeding with decisions before test results. Poorly coordinated diagnostic testing and the current oncology reimbursement model are barriers to the use of genomic and molecular diagnostic tests in cancer care.
    Journal of Oncology Practice 07/2012; 8(4):e24-31. DOI:10.1200/JOP.2011.000448

Preview

Download
0 Downloads
Available from